Akeso

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests whether adding two experimental drugs (AK117 and AK112) to standard chemotherapy can shrink tumors in people with advanced triple-negative breast cancer that hasn't been treated yet. About 120 participants will receive the combination. The main goals are to see h…

This study tests two experimental drugs, AK112 and cadonilimab, combined with standard chemotherapy as a first treatment for people with metastatic pancreatic cancer. About 110 participants will receive the combination to see if it is safe and helps shrink tumors. The goal is to …

This study tests two experimental immunotherapy drugs, AK112 and AK104, given together with or without standard chemotherapy. The goal is to see if this combination can safely shrink tumors and control advanced non-small cell lung cancer. About 233 adults with stage IIIB/IV lung …

This phase 3 trial compares a new drug, AK112, to the standard drug pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). About 398 participants with stage IIIB/C or IV cancer will receive either AK112 …

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This study tests two immunotherapy drugs, AK119 and AK112, alone or with chemotherapy, in 170 people with a common type of colorectal cancer (pMMR/MSS). The goal is to see if these combinations shrink tumors and are safe. The trial is active but not recruiting new participants.

This phase 3 trial tests whether adding the experimental drug AK112 (ivonescimab) to standard chemotherapy can help people with a certain type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) whose cancer has worsened after targeted therapy. About 322 participants will re…

This phase II trial is testing a new drug called AK112, alone or with chemotherapy, in people with resectable non-small cell lung cancer. The goal is to see if giving the treatment before and after surgery can help shrink tumors and prevent the cancer from coming back. The study …

This phase II trial tests a new drug called AK112, which targets both PD1 and VEGF, combined with standard chemotherapy in 265 people with advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination can shrink tumors and improve outcomes. Participants have …

This Phase 3 trial is testing whether a new immunotherapy drug called AK112, when combined with standard chemotherapy, works better than another immunotherapy (durvalumab) plus the same chemo for people with advanced bile duct cancer. The study includes 682 participants who have …

This Phase 3 trial is testing whether adding the immunotherapy AK104 to standard chemotherapy (with or without bevacizumab) helps people with advanced cervical cancer that cannot be cured by surgery or radiation. About 445 participants will receive either the drug combo or a plac…

This study tests two experimental drugs, AK112 and AK117, alone or together, in people with metastatic colorectal cancer that cannot be removed with surgery. The goal is to see if the drugs can shrink tumors or slow the disease. About 254 participants will be enrolled, and the st…

This study checks whether a drug called AK112 made at a new factory works the same in the body as the one from the original factory. It involves 108 healthy Chinese men aged 18 to 45. The goal is to measure how the drug moves through the body, not to treat any disease.